<DOC>
	<DOC>NCT00088270</DOC>
	<brief_summary>Multi-center, randomized Phase II study to evaluate the efficacy and safety of OSI-7904Lversus 5 FU/LV in biliary tract cancer.</brief_summary>
	<brief_title>A Study of OSI-7904L Versus 5-FU/LV as Treatment in Patients With Biliary Tract Cancer</brief_title>
	<detailed_description />
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Documented locally advanced or metastatic adenocarcinoma of the biliary tract; Adequate bone marrow, hepatic and renal function; Bilirubin &lt;= 1.5 times the upper limit of normal; Age 18 years or older; Predicted life expectancy 12 weeks or more; Prior surgery and radiation therapy permitted provided patient has recovered adequately; At least 1 target lesion &gt;= 20 mm (or &gt;= 10 mm on spiral CTscan); ECOG Performance Status 02; No prior chemotherapy for locally advanced or metastatic disease. Adjuvant/neoadjuvant permitted if therapy was completed at least 12 months prior to study entry; Concurrent anticancer therapy while on study; History of other malignancy within the past 3 years except basal or squamous cell carcinoma or in situ cervical cancer; Symptomatic brain metastases which are not stable or have required radiation in the past 28 days;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2004</verification_date>
</DOC>